drug
VAX-31
Phase 3updated 5mo agoby $PCVX Vaxcyte, Inc.
Phase 3community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying VAX-31
News(4)
- STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine marketVaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.stat · 2h ago
- Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shotsVaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest.fiercebiotech · 6h ago
- Chutes & Ladders—Longtime Takeda R&D chief to depart next JuneTakeda President of Research and Development Andy Plump, M.D., Ph.D., is leaving the company in June after twelve years in the position.fiercebiotech · 24d ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that